Eriodictyol-7-O-glucoside, a novel Nrf2 activator, confers protection against cisplatin-induced toxicity

被引：67

作者：

Hu, Qingwen ^{[1
]}

Zhang, Donna D. ^{[2
]}

Wang, Limei ^{[1
]}

Lou, Hongxiang ^{[1
]}

Ren, Dongmei ^{[1
]}

机构：

[1] Shandong Univ, Sch Pharmaceut Sci, Dept Nat Prod Chem, Jinan 250012, Peoples R China

[2] Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA

来源：

FOOD AND CHEMICAL TOXICOLOGY | 2012年 / 50卷 / 06期

基金：

中国国家自然科学基金;

关键词：

Eriodictyol-7-O-glucoside; Nrf2; Activate; Cisplatin; Toxicity; NRF2/HO-1 SIGNALING PATHWAY; INDUCED NEPHROTOXICITY; OXIDATIVE STRESS; DRACOCEPHALUM-RUPESTRE; HEME OXYGENASE-1; CELLS; SULFORAPHANE; DAMAGE; STABILIZATION; CHEMOTHERAPY;

D O I：

10.1016/j.fct.2012.03.059

中图分类号：

TS2 [食品工业];

学科分类号：

100403 [营养与食品卫生学];

摘要：

Eriodictyol-7-O-glucoside, a flavonoid isolated from Dracocephalum rupestre, is among the most potent free radical scavenger. In the present study, we identified eriodictyol-7-O-glucoside as a novel nuclear factor E2-related factor 2 (Nrf2) activator using a high-throughput cellular screening method. This compound activated Nrf2 signaling pathway and was able to stabilize Nrf2 by delaying Nrf2 degradation, resulting in accumulation of Nrf2 protein and activation of the Nrf2-dependent protective response. Recent studies have suggested that activation of Nrf2 pathway would confer protection against cisplatin-induced toxicity. The protective role of eriodictyol-7-O-glucoside in cisplatin-induced toxicity was investigated in a human renal mesangial cell line, HRMC. Cotreatment of HRMC cells with eriodictyol-7-O-glucoside significantly improved cell survival under cisplatin exposure. These findings demonstrated the feasibility of using natural compounds targeting Nrf2 as a therapeutic approach to subvert the side effects of cisplatin in normal cells. (C) 2012 Elsevier Ltd. All rights reserved.

引用

页码：1927 / 1932

页数：6

共 31 条

[1]

Transcriptional Regulation of Renal Cytoprotective Genes by Nrf2 and Its Potential Use as a Therapeutic Target to Mitigate Cisplatin-Induced Nephrotoxicity [J].